Cargando…

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy

Immune checkpoint inhibitors (ICI) have achieved unprecedented clinical success in cancer treatment. However, drug resistance to ICI therapy is a major hurdle that prevents cancer patients from responding to the treatment or having durable disease control. Drug repurposing refers to the application...

Descripción completa

Detalles Bibliográficos
Autores principales:	To, Kenneth K. W., Cho, William C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459070/ https://www.ncbi.nlm.nih.gov/pubmed/37631380 http://dx.doi.org/10.3390/pharmaceutics15082166

Ejemplares similares

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
por: Chen, Xunrui, et al.
Publicado: (2022)

Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy
por: Ye, Jiayi, et al.
Publicado: (2022)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
por: Rodriguez-Pascual, Jesus, et al.
Publicado: (2019)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
por: Lao, Yefang, et al.
Publicado: (2022)

A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors
por: Wei, Yuming, et al.
Publicado: (2016)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs
por: Sakai, Norihiro, et al.
Publicado: (2023)

Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015)

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
por: Shin, Dong Ho, et al.
Publicado: (2021)

Mechanisms of resistance to immune checkpoint inhibitors
por: Jenkins, Russell W, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
por: Dine, Jennifer, et al.
Publicado: (2017)

Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
por: Qian, Fang-Fei, et al.
Publicado: (2020)

Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
por: Dobosz, Paula, et al.
Publicado: (2022)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Multidrug Resistance in Cancer Circumvented Using a Cytosolic Drug Reservoir
por: Fan, Li, et al.
Publicado: (2017)

The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
por: Mpakali, Anastasia, et al.
Publicado: (2021)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

Immune checkpoints, their control by immunotherapy and ovarian cancer
por: Bose, Chinmoy K.
Publicado: (2017)

Immune checkpoint signaling and cancer immunotherapy
por: He, Xing, et al.
Publicado: (2020)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
por: Marei, Hany E., et al.
Publicado: (2023)

Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
por: Spitschak, Alf, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Mechanism of resistance to immune checkpoint inhibitors
por: Pandey, Manu R., et al.
Publicado: (2019)

Resistance to Checkpoint Inhibition in Cancer Immunotherapy
por: Barrueto, Luisa, et al.
Publicado: (2020)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Marine Natural Products as Models to Circumvent Multidrug Resistance
por: Long, Solida, et al.
Publicado: (2016)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023)

Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
por: Tateo, Valentina, et al.
Publicado: (2020)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer
por: Liu, Juan, et al.
Publicado: (2021)

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
por: Franzese, Ornella, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kaaqgm8l7h6tsqieev26pilsis